Q2 results exceeded expectations for revenue, margins, and EPS, driven by strong vascular and surgical segments, while interventional faced integration delays. Guidance was updated: revenue growth lowered to 3.5%-4.5%, but adjusted EPS raised to $6.90-$7.20. Strategic divestitures, capital returns…
Q2 results exceeded expectations for revenue, margins, and EPS, driven by strong vascular and surgical segments, while interventional faced integration delays. Guidance was updated: revenue growth lowered to 3.5%-4.5%, but adjusted EPS raised to $6.90-$7.20. Strategic divestitures, capital returns, and innovation milestones position the company for improved performance in 2027.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
